Found: 67
Select item for more details and to access through your institution.
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00988-x
- By:
- Publication type:
- Article
Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
- Published in:
- Journal of Oncology, 2020, p. 1, doi. 10.1155/2020/7131802
- By:
- Publication type:
- Article
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 23, p. 13144, doi. 10.3390/ijms222313144
- By:
- Publication type:
- Article
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
- Published in:
- Clinical & Experimental Medicine, 2022, v. 22, n. 2, p. 319, doi. 10.1007/s10238-021-00746-4
- By:
- Publication type:
- Article
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 10, p. 3201, doi. 10.3390/jcm9103201
- By:
- Publication type:
- Article
Thrombotic and bleeding complications in patients with AL amyloidosis.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 5, p. 1816, doi. 10.1111/bjh.19331
- By:
- Publication type:
- Article
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab‐based therapy.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 3, p. 411, doi. 10.1111/bjh.19042
- By:
- Publication type:
- Article
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 2, p. 356, doi. 10.1111/bjh.17841
- By:
- Publication type:
- Article
Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 1, p. 113, doi. 10.1111/bjh.17052
- By:
- Publication type:
- Article
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 1, p. 44, doi. 10.1111/bjh.13786
- By:
- Publication type:
- Article
Response of an oncology unit in the midst of the COVID-19 outbreak.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 8, p. 1947, doi. 10.1177/1078155220967973
- By:
- Publication type:
- Article
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 10, p. 1887, doi. 10.1002/ajh.27414
- By:
- Publication type:
- Article
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 502, doi. 10.1002/ajh.27219
- By:
- Publication type:
- Article
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1142, doi. 10.1002/ajh.26639
- By:
- Publication type:
- Article
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 12, p. 3355, doi. 10.3390/jcm11123355
- By:
- Publication type:
- Article
Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 11, p. 3088, doi. 10.3390/jcm11113088
- By:
- Publication type:
- Article
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2768, doi. 10.3390/cancers14112768
- By:
- Publication type:
- Article
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study.
- Published in:
- Cancers, 2021, v. 13, n. 20, p. 5057, doi. 10.3390/cancers13205057
- By:
- Publication type:
- Article
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4047, doi. 10.3390/cancers13164047
- By:
- Publication type:
- Article
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1257, doi. 10.3390/cancers13061257
- By:
- Publication type:
- Article
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3245, doi. 10.3390/cancers12113245
- By:
- Publication type:
- Article
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 2, p. 271, doi. 10.1111/ejh.13993
- By:
- Publication type:
- Article
Rituximab-Based Treatments in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 59
- By:
- Publication type:
- Article
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 468, doi. 10.1016/j.clml.2024.03.003
- By:
- Publication type:
- Article
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. 844, doi. 10.1016/j.clml.2023.07.013
- By:
- Publication type:
- Article
P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02336-3
- By:
- Publication type:
- Article
P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S104, doi. 10.1016/S2152-2650(21)02254-0
- By:
- Publication type:
- Article
P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02193-5
- By:
- Publication type:
- Article
MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S441, doi. 10.1016/S2152-2650(21)01982-0
- By:
- Publication type:
- Article
Poster: MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S253, doi. 10.1016/S2152-2650(21)01584-6
- By:
- Publication type:
- Article
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Screening for Gaucher disease in patients with plasma cell dyscrasias.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e327, doi. 10.1016/j.clml.2019.09.537
- By:
- Publication type:
- Article
Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e262, doi. 10.1016/j.clml.2019.09.433
- By:
- Publication type:
- Article
Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e184, doi. 10.1016/j.clml.2019.09.309
- By:
- Publication type:
- Article
Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e185, doi. 10.1016/j.clml.2019.09.310
- By:
- Publication type:
- Article
Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S331, doi. 10.1016/j.clml.2019.07.322
- By:
- Publication type:
- Article
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S325, doi. 10.1016/j.clml.2019.07.310
- By:
- Publication type:
- Article
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S237, doi. 10.1016/j.clml.2018.07.125
- By:
- Publication type:
- Article
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.114
- By:
- Publication type:
- Article
Oligosecretory and Non-Secretory Multiple Myeloma: Incidence, Clinical Characteristics and Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e115, doi. 10.1016/j.clml.2017.03.209
- By:
- Publication type:
- Article
Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e143, doi. 10.1016/j.clml.2017.03.259
- By:
- Publication type:
- Article
Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e65, doi. 10.1016/j.clml.2017.03.119
- By:
- Publication type:
- Article
Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e115, doi. 10.1016/j.clml.2017.03.210
- By:
- Publication type:
- Article
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 3, p. 704, doi. 10.3390/v15030704
- By:
- Publication type:
- Article